EDWARDS LIFESCIENCES CORP
EWNYSETrading Snapshot
- Day Range
- $87.31 β $89.33
- 52-Week Range
- $72.30 β $96.29
- Volume
- $4.58B
- Avg Volume
- $3.19B
- Shares Outstanding
- 575.8M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $6.07B
- Last Q Revenue
- $1.74B
- P/E Ratio
- 50.0
- P/S Ratio
- 7.7x
- EPS (TTM)
- $1.74
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β1.5%
Why Investors Own EW
- βHigh-growth profile β revenue up -8.4% YoY with expanding US Equity exposure.
- βHealthy economics β 45% gross margin and 6% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EDWARDS LIFESCIENCES CORP
EWAbout EDWARDS LIFESCIENCES CORP
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platfo

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

EW DCF Analysis: Intrinsic Value $53 vs Price $86
On September 16, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has experienced a mixed price performance recently. The

Edwards Lifesciences Comments on TAVR National Coverage Decision
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by

Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled t